1ST.AX 1st Group +22.22% pre-market ASX 19 Mar 2026: volume jump shows interest

1ST.AX stock rose 22.22% to A$0.011 in pre-market ASX trade on 19 Mar 2026. Volume hit 2,075,140 shares, roughly three times the five-day average. The move places 1st Group Limited (ASX: 1ST.AX) among today’s top gainers in the Healthcare sector. Market participants flagged higher-than-usual buying with limited news flow. We examine what drove the jump, the company’s valuation, and what Meyka AI’s models show next for this small-cap name.

1ST.AX stock: price action and trading flow

The immediate driver for 1ST.AX was a pre-market bid that lifted the price from A$0.009 to A$0.011, a +22.22% change. Intraday range remained tight with a day low and high at A$0.011, reflecting concentrated trades. High volume of 2,075,140 shares pushed relative volume to 3.06, signalling outsized demand versus the average of 678,621 shares.

What may have caused the move

There is no single public announcement from 1st Group Limited at the time of writing. The stock’s spike aligns with small-cap momentum seen across Healthcare, where speculative flows target thinly traded listings. Given the company’s marketplace and SaaS services, any contract or customer update could trigger further moves.

Financials and valuation metrics for 1ST.AX stock

Key metrics show a stressed balance with EPS A$-0.01 and PE -1.10, reflecting losses. Market cap is A$15,586,889.00 and shares outstanding are 1,416,989,952. Price-to-sales is 3.49 and current ratio sits at 0.83, which flags short-term liquidity pressure. Revenue per share is A$0.0034 while free cash flow per share is A$-0.0028.

Technicals and trading averages

Short-term momentum is positive: the price sits above the 50-day average A$0.009 and 200-day average A$0.008, indicating recent strength. Year range is A$0.004 to A$0.015, so today’s level is closer to the upper quartile. High rel‑volume often precedes further volatility in microcap names like this.

Meyka grade and forecast for 1ST.AX

Meyka AI rates 1ST.AX with a score of 65.38 out of 100 — Grade B (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects A$0.007 for 1ST.AX over the next year, implying about -36.36% versus the current price A$0.011. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context

Risks include thin liquidity, negative EPS, and a current ratio 0.83 that points to working capital strain. Catalysts that could lift the stock are customer wins for MyHealth1st, GoBookings SaaS contracts, or a strategic update. Healthcare sector weakness year-to-date contrasts with pockets of small-cap interest that can create sharp moves.

Final Thoughts

1ST.AX stock is trading as a pre-market top gainer after a 22.22% jump to A$0.011 on ASX on 19 Mar 2026, driven by a 2,075,140 share volume surge. The move reflects heightened short-term interest but sits against mixed fundamentals: negative EPS (A$-0.01), a low current ratio (0.83), and modest market cap (A$15,586,889.00). Meyka AI’s forecast model projects A$0.007 over the next year, implying roughly -36.36% from today’s price; this flags potential downside if no material operational improvement arrives. For traders, the stock offers short-term volatility and event-driven upside. For investors, the company needs clearer revenue growth and improved liquidity before a BUY grade is warranted. Use size limits and stop-losses in any trade given the microcap risk profile. For live order flow and company filings, check 1ST.AX on Meyka and verify company announcements directly.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.